Susquehanna International Group
CRVS icon

Susquehanna International Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Susquehanna International Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73M Sell
186,400
-73,800
-28% -$1.18M ﹤0.01% 5471
2025
Q4 		$2M Buy
260,200
+216,100
+490% +$1.7M ﹤0.01% 5660
2025
Q3 		$325K Buy
44,100
+16,700
+61% +$85.5K ﹤0.01% 9930
2025
Q2 		$110K Sell
27,400
-65,800
-71% -$239K ﹤0.01% 11740
2025
Q1 		$296K Sell
93,200
-31,100
-25% -$146K ﹤0.01% 10093
2024
Q4 		$665K Buy
124,300
+79,900
+180% +$596K ﹤0.01% 7966
2024
Q3 		$234K Buy
44,400
+30,000
+208% +$108K ﹤0.01% 10143
2024
Q2 		$26.2K Sell
14,400
-9,100
-39% -$17K ﹤0.01% 11601
2024
Q1 		$41.8K Sell
23,500
-17,900
-43% -$37.4K ﹤0.01% 11626
2023
Q4 		$72.9K Sell
41,400
-12,000
-22% -$17.5K ﹤0.01% 11530
2023
Q3 		$78K Sell
53,400
-21,500
-29% -$45.5K ﹤0.01% 11080
2023
Q2 		$172K Buy
+74,900
New +$156K ﹤0.01% 10431
2022
Q3 		– Sell
-17,200
Closed -$17K – 13286
2022
Q2 		$17K Sell
17,200
-9,300
-35% -$11.4K ﹤0.01% 12400
2022
Q1 		$43K Sell
26,500
-54,900
-67% -$101K ﹤0.01% 12368
2021
Q4 		$196K Sell
81,400
-129,800
-61% -$503K ﹤0.01% 11471
2021
Q3 		$1.02M Buy
211,200
+146,900
+228% +$435K ﹤0.01% 7507
2021
Q2 		$172K Sell
64,300
-24,500
-28% -$67.5K ﹤0.01% 11746
2021
Q1 		$274K Buy
88,800
+66,900
+305% +$242K ﹤0.01% 10787
2020
Q4 		$78K Buy
+21,900
New +$88.2K ﹤0.01% 10606

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's CRVS Position: Q1 2026 in Review

Susquehanna International Group reduced its Corvus Pharmaceuticals (CRVS) stake by 37% in Q1 2026, selling an estimated $369K and leaving 38,636 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #9352.

Susquehanna International Group first reported a position in CRVS in Q4 2019 and has held it in 20 quarters since. The position peaked at $5.43M in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Susquehanna International Group held 38,636 shares of Corvus Pharmaceuticals worth $565K as of Q1 2026.
  • Susquehanna International Group sold 23,118 Corvus Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9352 holding.
  • Susquehanna International Group first reported a position in Corvus Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Susquehanna International Group's Corvus Pharmaceuticals position peaked at $5.43M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.